---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-196086"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:53:37.457272+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Invivyd appoints Sara Cotter to Board; option for 100,000 shares

## Summary
- Sara Cotter appointed to Board effective July 25, 2023, increasing board size from 8 to 9.
- Cotter receives $40,000 annual cash retainer and nonqualified option for 100,000 shares vesting over 3 years.
- Cotter is Portfolio Manager for UBS Global Biotech Lux Fund and former CEO of Levo Therapeutics.
- Company advancing lead candidate VYD222; initial Phase 1 data positive and pivotal trial planned.

## SEC filing metadata
- accession: 0001193125-23-196086
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312523196086/0001193125-23-196086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312523196086/d875161d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-196086
- JSON: https://secwatch.observer/filing/0001193125-23-196086.json
- Plain text: https://secwatch.observer/filing/0001193125-23-196086.txt

## Key facts
- Executive change
  Sara Cotter was appointed as director at Invivyd, Inc..
  - Action: appointed
  - Role: director
  source text: appointed Sara Cotter as a director to fill the resulting vacancy, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312523196086/0001193125-23-196086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.